Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan ... EON: Enhanced Online News (press release) Continuing to advance the daclizumab Phase 3 program in MS. Building world-class scientific teams in its core therapeutic areas. Advancing the company's internal early-stage pipeline programs. Advancing existing strategic collaborations, ... |
